News stories about Calithera Biosciences (NASDAQ:CALA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Calithera Biosciences earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.925247197321 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

Several equities analysts have weighed in on the company. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research note on Monday, November 6th. William Blair assumed coverage on Calithera Biosciences in a research note on Thursday, October 5th. They set an “outperform” rating on the stock. Finally, BidaskClub cut Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $15.17.

Shares of Calithera Biosciences (NASDAQ CALA) traded up $0.50 during trading on Thursday, hitting $10.75. The stock had a trading volume of 798,900 shares, compared to its average volume of 752,170. Calithera Biosciences has a 1 year low of $2.90 and a 1 year high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. The business had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $6.02 million. sell-side analysts predict that Calithera Biosciences will post -0.77 earnings per share for the current year.

In related news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of Calithera Biosciences stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $15.64, for a total value of $9,008,640.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 16.30% of the company’s stock.

WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Insider Buying and Selling by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.